Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A E Wakeling

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Cancer Research|July 15, 1993
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780N Brünner, T L Frandsen, C Holst-Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancerR A McClelland, J M Gee, A B Francis, et al.
Breast Cancer Research and Treatment|January 1, 1996
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesA E Wakeling, A J Barker, D H Davies, et al.
Journal of the National Cancer Institute|May 17, 1995
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancerC K Osborne, E B Coronado-Heinsohn, S G Hilsenbeck, et al.
Endocrine-Related Cancer|December 23, 2004
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsH E Jones, L Goddard, J M W Gee, et al.
Endocrine-Related Cancer|September 22, 2001
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Annals of the New York Academy of Sciences|July 4, 2002
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Breast Cancer Research and Treatment|January 1, 1996
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genesR A McClelland, D L Manning, J M Gee, et al.
Endocrinology|September 10, 2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitroJ M W Gee, M E Harper, I R Hutcheson, et al.
Cancer Research|September 18, 2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerJ F Robertson, R I Nicholson, N J Bundred, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cancer Research|July 15, 1993
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780N Brünner, T L Frandsen, C Holst-Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancerR A McClelland, J M Gee, A B Francis, et al.
Breast Cancer Research and Treatment|January 1, 1996
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesA E Wakeling, A J Barker, D H Davies, et al.
Journal of the National Cancer Institute|May 17, 1995
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancerC K Osborne, E B Coronado-Heinsohn, S G Hilsenbeck, et al.
Endocrine-Related Cancer|December 23, 2004
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsH E Jones, L Goddard, J M W Gee, et al.
Endocrine-Related Cancer|September 22, 2001
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Annals of the New York Academy of Sciences|July 4, 2002
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Breast Cancer Research and Treatment|January 1, 1996
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genesR A McClelland, D L Manning, J M Gee, et al.
Endocrinology|September 10, 2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitroJ M W Gee, M E Harper, I R Hutcheson, et al.
Cancer Research|September 18, 2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerJ F Robertson, R I Nicholson, N J Bundred, et al.
Pageof 6